Territory: Central and Western United States

The MSL, Oncology (Skin Cancers) will join a fast-growing Field Medical Affairs team focused on commercializing the novel Signatera™ molecular residual disease (MRD) test. This role is dedicated to supporting oncologists and cancer researchers across solid tumors—with a primary emphasis on skin cancers—alongside complementary products and services within Natera's oncology portfolio.

In 2019, the FDA designated Signatera as a Breakthrough Device, and Medicare proposed coverage for its use in patients with Stage II–III colorectal cancer as its first indication. We are seeking a smart, mission-oriented Medical Affairs professional who can communicate effectively to help transform the management of cancer worldwide. The MSL serves as a vital field-based scientific resource for clinicians, academic institutions, and prof...